Systematic review of protein biomarkers of invasive behavior in glioblastoma

Molecular Neurobiology

Volumn 49, Issue 3, 2014, Pages 1212-1244

  Sayegh, Eli T ^a   Kaur, Gurvinder ^a   Bloch, Orin ^a   Parsa, Andrew T ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Glioblastoma; High grade glioma; Invasion; Invasiveness; Protein biomarkers

Indexed keywords

ANGIOGENIC FACTOR; BIOLOGICAL MARKER; CALPAIN 2; CATHEPSIN B; CATHEPSIN D; CATHEPSIN S; CELL ADHESION MOLECULE; CHEMOKINE; COLLAGENASE 3; CYSTEINE RICH PROTEIN 61; CYTOKINE; EZRIN; FASCIN; GALECTIN 1; GALECTIN 3; GELATINASE A; GELATINASE B; MATRIX METALLOPROTEINASE 14; OSTEONECTIN; OSTEOPONTIN; PLACENTA PROTEIN 5; PLASMINOGEN ACTIVATOR INHIBITOR 1; SCLEROPROTEIN; TEMOZOLOMIDE; TENASCIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 4; TRANSCRIPTION FACTOR; UNINDEXED DRUG; VASCULOTROPIN; TUMOR MARKER;

CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; GLIOBLASTOMA; HUMAN; MEMBRANE CHANNEL; OUTCOME ASSESSMENT; PHENOTYPE; REVIEW; SIGNAL TRANSDUCTION; SYSTEMATIC REVIEW; TREATMENT FAILURE; TUMOR INVASION; ANIMAL; BRAIN NEOPLASMS; METABOLISM; PATHOLOGY;

ANIMALS; BRAIN NEOPLASMS; GLIOBLASTOMA; HUMANS; NEOPLASM INVASIVENESS; TUMOR MARKERS, BIOLOGICAL;

EID: 84902553619     PISSN: 08937648     EISSN: 15591182     Source Type: Journal    
DOI: 10.1007/s12035-013-8593-5     Document Type: Review

References (320)

1. Wen PY, Kesari S (2008) Malignant gliomas in adults. N Engl J Med 359:492-507. doi:10.1056/NEJMra0708126
2. Verhoeff JJC, Van Tellingen O, Claes A et al (2009) Concerns about anti-angiogenic treatment in patients with glioblastoma multiforme. BMC Cancer 9:444. doi:10.1186/1471-2407-9-444
3. Stupp R, Mason WP, Van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987-96. doi:10.1056/NEJMoa043330 (Pubitemid 40349501)
4. Reddy SP, Britto R, Vinnakota K et al (2008) Novel glioblastoma markers with diagnostic and prognostic value identified through transcriptome analysis. Clin Cancer Res An Off J Am Assoc Cancer Res 14:2978-87. doi:10.1158/1078-0432. CCR-07-4821
5. Kong D-S, Song S-Y, Kim D-H et al (2009) Prognostic significance of c-Met expression in glioblastomas. Cancer 115:140-8. doi:10.1002/cncr.23972
6. Hormigo A, Gu B, Karimi S et al (2006) YKL-40 and matrix metalloproteinase-9 as potential serum biomarkers for patients with high-grade gliomas. Clin Cancer Res An Off J Am Assoc Cancer Res 12:5698-704. doi:10.1158/1078-0432.CCR-06-0181 (Pubitemid 44629598)
7. Shirahata M, Iwao-Koizumi K, Saito S et al (2007) Gene expression-based molecular diagnostic system for malignant gliomas is superior to histological diagnosis. Clin Cancer Res 13:7341-7356. doi:10.1158/1078-0432.CCR-06-2789
8. Khoshyomn S, Lew S, DeMattia J et al (1999) Brain tumor invasion rate measured in vitro does not correlate with Ki-67 expression. J Neuro-Oncol 45:111-6 (Pubitemid 30197724)
9. Verhaak RG, Hoadley KA, Purdom E et al (2010) Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17:98-110. doi:10.1016/j.ccr.2009.12.020
10. Sawyers CL (2008) The cancer biomarker problem. Nature 452:548-552. doi:10.1038/nature06913
11. Jang HS, Lal S, Greenwood JA (2010) Calpain 2 is required for glioblastoma cell invasion: regulation ofmatrixmetalloproteinase 2. Neurochem Res 35:1796-804. doi:10.1007/s11064-010-0246-8
12. Joy AM, Beaudry CE, Tran NL et al (2003) Migrating glioma cells activate the PI3-K pathway and display decreased susceptibility to apoptosis. J Cell Sci 116:4409-4417. doi:10.1242/jcs.00712 (Pubitemid 37369596)
13. Lefranc F, Brotchi J, Kiss R (2005) Possible future issues in the treatment of glioblastomas: special emphasis on cell migration and the resistance of migrating glioblastoma cells to apoptosis. J Clin Oncol: Off J Am Soc Clin Oncol 23:2411-22. doi:10.1200/JCO. 2005.03.089
14. Kislin KL, McDonough WS, Eschbacher JM et al (2009) NHERF-1:modulator of glioblastoma cellmigration and invasion. Neoplasia 11:377-387
15. Wild-Bode C, Weller M, Rimner A et al (2001) Sublethal irradiation promotes migration and invasiveness of glioma cells: implications for radiotherapy of human glioblastoma. Cancer Res 61:2744-2750 (Pubitemid 32685864)
16. Norden AD, Young GS, Setayesh K et al (2008) Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology 70:779-87. doi:10.1212/01.wnl.0000304121.57857.38
17. Narayana A, Kelly P, Golfinos J et al (2009) Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival. J Neurosurg 110:173-80. doi:10.3171/2008.4.17492
18. Hoelzinger DB, Mariani L, Weis J et al (2005) Gene expression profile of glioblastoma multiforme invasive phenotype points to new therapeutic targets. Neoplasia 7:7-16. doi:10.1593/neo.04535 (Pubitemid 40209466)
19. Wang L, Liu Q, Zhao H et al (2013) Differential effects of low- and high-dose GW2974, a dual epidermal growth factor receptor and HER2 kinase inhibitor, on glioblastoma multiforme invasion. J Neurosci Res 91:128-37. doi:10.1002/jnr.23140
20. Hirata E, Arakawa Y, Shirahata M et al (2009) Endogenous tenascin-C enhances glioblastoma invasion with reactive change of surrounding brain tissue. Cancer Sci 100:1451-1459. doi:10.1111/j.1349-7006.2009.01189.x
21. Fowler A, Thomson D, Giles K et al (2011) miR-124a is frequently down-regulated in glioblastoma and is involved in migration and invasion. Eur J Cancer 47:953-963. doi:10.1016/j.ejca.2010.11.026
22. Parsa AT, Wachhorst S, Lamborn KR et al (2005) Prognostic significance of intracranial dissemination of glioblastoma multiforme in adults. J Neurosurg 102:622-628. doi:10.3171/jns.2005.102.4.0622 (Pubitemid 43186665)
23. Johansen JS, Jensen BV, Roslind A et al (2006) Serum YKL-40, a new prognostic biomarker in cancer patients? Cancer Epidemiol Biomarkers Prev 15:194 - 202. doi:10.1158/1055-9965.EPI-05-0011
24. Jansen M, Yip S, Louis DN (2010) Molecular pathology in adult gliomas: diagnostic, prognostic, and predictive markers. Lancet Neurol 9:717-726. doi:10.1016/S1474-4422(10)70105-8
25. Hegi ME, Diserens A-C, Gorlia T et al (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997-1003. doi:10.1056/NEJMoa043331 (Pubitemid 40349502)
26. Kachra Z, Beaulieu E, Delbecchi L et al (1999) Expression of matrix metalloproteinases and their inhibitors in human brain tumors. Clin Exp Metastasis 17:555-66 (Pubitemid 30337129)
27. Kondraganti S, Mohanam S, Chintala SK et al (2000) Selective suppression of matrix metalloproteinase-9 in human glioblastoma cells by antisense gene transfer impairs glioblastoma cell invasion. Cancer Res 60:6851-5 (Pubitemid 32059151)
28. NakadaM, Nakamura H, Ikeda E et al (1999) Expression and tissue localization ofmembrane-type 1, 2, and 3matrixmetalloproteinases in human astrocytic tumors. Am J Pathol 154:417-28. doi:10.1016/S0002-9440(10)65288-1 (Pubitemid 29094092)
29. Choe G, Park JK, Jouben-Steele L et al (2002) Active matrix metalloproteinase 9 expression is associated with primary glioblastoma subtype. Clin Cancer Res Off J Am Assoc Cancer Res 8:2894-901 (Pubitemid 35025737)
30. Lakka SS, Rajan M, Gondi C et al (2002) Adenovirus-mediated expression of antisense MMP-9 in glioma cells inhibits tumor growth and invasion. Oncogene 21:8011-9. doi:10.1038/sj.onc.1205894 (Pubitemid 35434187)
31. Lakka SS, Jasti SL, Gondi C et al (2002) Downregulation of MMP-9 in ERK-mutated stable transfectants inhibits glioma invasion in vitro. Oncogene 21:5601-8. doi:10.1038/sj.onc.1205646 (Pubitemid 34983550)
32. Yamamoto M, Sawaya R, Mohanam S et al (1994) Expression and cellular localization of messenger RNA for plasminogen activator inhibitor type 1 in human astrocytomas in vivo. Cancer Res 54:3329-3332 (Pubitemid 24225941)
33. NakadaM, Kita D, Futami K et al (2001) Roles ofmembrane type 1 matrix metalloproteinase and tissue inhibitor of metalloproteinases 2 in invasion and dissemination of human malignant glioma. J Neurosurg 94:464-73. doi:10.3171/jns.2001.94.3.0464 (Pubitemid 32786027)
34. Nuttall RK, Pennington CJ, Taplin J et al (2003) Elevated membrane-type matrix metalloproteinases in gliomas revealed by profiling proteases and inhibitors in human cancer cells. Mol Cancer Res MCR 1:333-45 (Pubitemid 36437920)
35. Raithatha SA, Muzik H, Rewcastle NB et al (2000) Localization of gelatinase-A and gelatinase-B mRNA and protein in human gliomas. Neuro-Oncology 2:145-50
36. Colin C, Voutsinos-Porche B, Nanni I et al (2009) High expression of cathepsin B and plasminogen activator inhibitor type-1 are strong predictors of survival in glioblastomas. Acta Neuropathol 118:745-754. doi:10.1007/s00401-009- 0592-2
37. Yan W, Zhang W, Sun L et al (2011) Identification of MMP-9 specific microRNA expression profile as potential targets of antiinvasion therapy in glioblastoma multiforme. Brain Res 1411:108-15. doi:10.1016/j.brainres.2011.07. 002
38. Kunishio K, Okada M, Matsumoto Y, Nagao S (2003) Matrix metalloproteinase-2 and -9 expression in astrocytic tumors. Brain Tumor Pathol 20:39-45 (Pubitemid 38146269)
39. Badiga AV, Chetty C, Kesanakurti D et al (2011) MMP-2 siRNA inhibits radiation-enhanced invasiveness in glioma cells. PloS One 6:e20614. doi:10.1371/journal.pone.0020614
40. Inoue A, Takahashi H, Harada H et al (2010) Cancer stem-like cells of glioblastoma characteristically express MMP-13 and display highly invasive activity. Int J Oncol 37:1121-31
41. Hotary K, Allen E, Punturieri A et al (2000) Regulation of cell invasion and morphogenesis in a three-dimensional type I collagen matrix by membrane-type matrix metalloproteinases 1, 2, and 3. J Cell Biol 149:1309-23 (Pubitemid 30399683)
42. Guo P, Imanishi Y, Cackowski FC et al (2005) Up-regulation of angiopoietin-2, matrix metalloprotease-2, membrane type 1 metalloprotease, and laminin 5 gamma 2 correlates with the invasiveness of human glioma. Am J Pathol 166:877-90 (Pubitemid 40315644)
43. Markovic DS, Vinnakota K, Chirasani S et al (2009) Gliomas induce and exploit microglial MT1-MMP expression for tumor expansion. Proc Natl Acad Sci U S A 106:12530-5. doi:10.1073/pnas.0804273106
44. Sreekanthreddy P, Srinivasan H, Kumar DM et al (2010) Identification of potential serum biomarkers of glioblastoma: serum osteopontin levels correlate with poor prognosis. Cancer Epidemiol Biomarkers Prev 19:1409-1422. doi:10.1158/1055-9965.EPI-09-1077
45. Rorive S, Lopez XM, Maris C et al (2010) TIMP-4 and CD63: new prognostic biomarkers in human astrocytomas. Mod Pathol 23:1418-1428. doi:10.1038/ modpathol.2010.136
46. Crocker M, Ashley S, Giddings I et al (2011) Serum angiogenic profile of patients with glioblastoma identifies distinct tumor subtypes and shows that TIMP-1 is a prognostic factor. Neuro-Oncol 13:99-108. doi:10.1093/neuonc/noq170
47. Aaberg-Jessen C, Christensen K, Offenberg H et al (2009) Low expression of tissue inhibitor of metalloproteinases-1 (TIMP-1) in glioblastoma predicts longer patient survival. J Neuro-Oncol 95:117-28. doi:10.1007/s11060-009-9910-8
48. Groft LL, Muzik H, Rewcastle NB et al (2001) Differential expression and localization of TIMP-1 and TIMP-4 in human gliomas. Br J Cancer 85:55-63. doi:10.1054/bjoc.2001.1854 (Pubitemid 32695716)
49. Rorive S, Maris C, Debeir O et al (2006) Exploring the distinctive biological characteristics of pilocytic and low-grade diffuse astrocytomas using microarray gene expression profiles. J Neuropathol Exp Neurol 65:794 - 807. doi:10.1097/01.jnen.0000228203.12292.a1
50. Correa TC, Brohem CA, Winnischofer SM et al (2006) Downregulation of the RECK-tumor and metastasis suppressor gene in glioma invasiveness. J Cell Biochem 99:156-167. doi:10.1002/jcb.20917 (Pubitemid 44297960)
51. Silveira Correa TC, Massaro RR, Brohem CA et al (2010) RECK-mediated inhibition of glioma migration and invasion. J Cell Biochem 110:52-61. doi:10.1002/jcb.22472
52. Gondi CS, Lakka SS, Yanamandra N et al (2003) Expression of antisense uPAR and antisense uPA from a bicistronic adenoviral construct inhibits glioma cell invasion, tumor growth, and angiogenesis. Oncogene 22:5967-75. doi:10.1038/sj.onc.1206535 (Pubitemid 37175875)
53. Mohanam S, Chintala SK, Go Y et al (1997) In vitro inhibition of human glioblastoma cell line invasiveness by antisense uPA receptor. Oncogene 14:1351-9. doi:10.1038/sj.onc.1200963 (Pubitemid 27151992)
54. Lakka SS, Gondi CS, Yanamandra N et al (2003) Synergistic down-regulation of urokinase plasminogen activator receptor and matrix metalloproteinase-9 in SNB19 glioblastoma cells efficiently inhibits glioma cell invasion, angiogenesis, and tumor growth. Cancer Res 63:2454-61 (Pubitemid 36605183)
55. Go Y, Chintala SK, Mohanam S et al (1997) Inhibition of in vivo tumorigenicity and invasiveness of a human glioblastoma cell line transfected with antisense uPAR vectors. Clin Exp Metastasis 15:440-6 (Pubitemid 27285818)
56. Lakka SS, Gondi CS, Dinh DH et al (2005) Specific interference of urokinase-type plasminogen activator receptor and matrix metalloproteinase-9 gene expression induced by double-stranded RNA results in decreased invasion, tumor growth, and angiogenesis in gliomas. J Biol Chem 280:21882 - 21892. doi:10.1074/jbc.M408520200
57. Muracciole X, Romain S, Dufour H et al (2002) PAI-1 and EGFR expression in adult glioma tumors: toward a molecular prognostic classification. Int J Radiat Oncol Biol Phys 52:592-598 (Pubitemid 34158718)
58. Takahashi S, Yamada-Okabe H, Hamada K et al (2011) Downregulation of uPARAP mediates cytoskeletal rearrangements and decreases invasion and migration properties in glioma cells. J Neuro-Oncol 103:267-76. doi:10.1007/s11060-010- 0398-z
59. Hjortland GO, Bjornland K, Pettersen S et al (2003) Modulation of glioma cell invasion and motility by adenoviral gene transfer of PAI-1. Clin Exp Metastasis 20:301-309 (Pubitemid 36745658)
60. Kono S, Rao JS, Bruner JM, Sawaya R (1994) Immunohistochemical localization of plasminogen activator inhibitor type 1 in human brain tumors. J Neuropathol Exp Neurol 53:256-262 (Pubitemid 24146863)
61. Iwadate Y, Hayama M, Adachi A et al (2008) High serum level of plasminogen activator inhibitor-1 predicts histological grade of intracerebral gliomas. Anticancer Res 28:415-418 (Pubitemid 351362846)
62. Gessler F, Voss V, Seifert V et al (2011) Knockdown of TFPI-2 promotes migration and invasion of glioma cells. Neurosci Let 497:49-54
63. Rao CN, Lakka SS, Kin Y et al (2001) Expression of tissue factor pathway inhibitor 2 inversely correlates during the progression of human gliomas. Clin Cancer Res 7:570-576 (Pubitemid 32707980)
64. Gole B, Duran Alonso MB, Dolenc V, Lah T (2009) Post-translational regulation of cathepsin B, but not of other cysteine cathepsins, contributes to increased glioblastoma cell invasiveness in vitro. Pathol Oncol Res 15:711-723. doi:10.1007/s12253-009-9175-8
65. Gondi CS, Lakka SS, Yanamandra N et al (2004) Adenovirus-mediated expression of antisense urokinase plasminogen activator receptor and antisense cathepsin B inhibits tumor growth, invasion, and angiogenesis in gliomas. Cancer Res 64:4069-77. doi:10.1158/0008-5472.CAN-04-1243 (Pubitemid 38807311)
66. Lakka SS, Gondi CS, Yanamandra N et al (2004) Inhibition of cathepsin B and MMP-9 gene expression in glioblastoma cell line via RNA interference reduces tumor cell invasion, tumor growth and angiogenesis. Oncogene 23:4681 -9. doi:10.1038/sj.onc.1207616
67. Flannery T, Gibson D, Mirakhur M et al (2003) The clinical significance of cathepsin S expression in human astrocytomas. Am J Pathol 163:175-82. doi:10.1016/S0002-9440(10)63641-3 (Pubitemid 36759602)
68. Flannery T, McQuaid S, McGoohan C et al (2006) Cathepsin S expression: an independent prognostic factor in glioblastoma tumours - a pilot study. Int J Cancer J Int du Cancer 119:854-60. doi:10.1002/ijc.21911 (Pubitemid 44051449)
69. Fukuda ME, Iwadate Y, Machida T et al (2005) Cathepsin D is a potential serum marker for poor prognosis in glioma patients. Cancer Res 65:5190-4. doi:10.1158/0008-5472.CAN-04-4134 (Pubitemid 40827328)
70. Kast RE (2010) Glioblastoma invasion, cathepsin B, and the potential for both to be inhibited by auranofin, an old anti-rheumatoid arthritis drug. Central Eur Neurosurg 71:139-42. doi:10.1055/s-0029-1242756
71. Lu Y, Jiang F, Zheng X et al (2011) TGF-β1 promotes motility and invasiveness of glioma cells through activation of ADAM17. Oncology Reports 25:1329-35. doi:10.3892/or.2011.1195
72. Wildeboer D, Naus S, Amy Sang QX et al (2006) Metalloproteinase disintegrins ADAM8 and ADAM19 are highly regulated in human primary brain tumors and their expression levels and activities are associated with invasiveness. J Neuropathol Exp Neurol 65:516-527. doi:10.1097/01 (Pubitemid 44297273)
73. Zheng X, Jiang F, Katakowski M et al (2007) Inhibition of ADAM17 reduces hypoxia-induced brain tumor cell invasiveness. Cancer Sci 98:674-84. doi:10.1111/j.1349-7006.2007.00440.x (Pubitemid 46563443)
74. Chen X, Chen L, Chen J et al (2013) ADAM17 promotes U87 glioblastoma stem cell migration and invasion. Brain Res. doi:10.1016/j.brainres.2013.02.025
75. Chen X, Chen L, Zhang R et al (2013) ADAM17 regulates self-renewal and differentiation of U87 glioblastoma stem cells. Neurosci Lett 537:44-9. doi:10.1016/j.neulet.2013.01.021
76. Nakada M, Miyamori H, Kita D et al (2005) Human glioblastomas overexpress ADAMTS-5 that degrades brevican. Acta Neuropathol 110:239-246. doi:10.1007/s00401-005-1032-6 (Pubitemid 41430652)
77. Borgono CA, Diamandis EP (2004) The emerging roles of human tissue kallikreins in cancer. Nat Rev Cancer 4:876-890 (Pubitemid 39472954)
78. Prezas P, Scorilas A, Yfanti C et al (2006) The role of human tissue kallikreins 7 and 8 in intracranial malignancies. Biol Chem 387:1607-1612. doi:10.1515/BC.2006.200 (Pubitemid 44837586)
79. Lal A, Lash AE, Altschul SF et al (1999) A public database for gene expression in human cancers. Cancer Res 59:5403-5407 (Pubitemid 29526444)
80. Liu L, Wu J, Ying Z et al (2010) Astrocyte elevated gene-1 upregulates matrix metalloproteinase-9 and induces human glioma invasion. Cancer Res 70:3750-3759. doi:10.1158/0008-5472.CAN-09-3838
81. Emdad L, Sarkar D, Lee SG et al (2010) Astrocyte elevated gene-1: a novel target for human glioma therapy.Mol Cancer Ther 9:79-88. doi:10.1158/1535-7163. MCT-09-0752
82. Sarkar D, Park ES, Emdad L et al (2008) Molecular basis of nuclear factor-kappaB activation by astrocyte elevated gene-1. Cancer Res 68:1478-1484. doi:10.1158/0008-5472.CAN-07-6164 (Pubitemid 351346856)
83. Markert JM, Fuller CM, Gillespie GYet al (2001) Differential gene expression profiling in human brain tumors. Physiol Genomics 5:21-33 (Pubitemid 33675199)
84. Shostak K, Labunskyy V, Dmitrenko Vet al (2003) HC gp-39 gene is upregulated in glioblastomas. Cancer Lett 198:203-210 (Pubitemid 37297793)
85. Tanwar MK, Gilbert MR, Holland EC (2002) Gene expression microarray analysis reveals YKL-40 to be a potential serum marker for malignant character in human glioma. Cancer Res 62:4364-4368 (Pubitemid 34827294)
86. Nigro JM, Misra A, Zhang L et al (2005) Integrated array-comparative genomic hybridization and expression array profiles identify clinically relevant molecular subtypes of glioblastoma. Cancer Res 65:1678-1686. doi:10.1158/0008-5472.CAN-04-2921 (Pubitemid 40478592)
87. Pelloski CE, Mahajan A, Maor M et al (2005) YKL-40 expression is associated with poorer response to radiation and shorter overall survival in glioblastoma. Clin Cancer Res Off J Am Assoc Cancer Res 11:3326-34. doi:10.1158/1078-0432.CCR-04-1765 (Pubitemid 40627883)
88. Iwamoto FM, Hottinger AF, Karimi S et al (2011) SerumYKL-40 is a marker of prognosis and disease status in high-grade gliomas. Neuro Oncol 13(11):1244-1251
89. Ku BM, Lee YK, Ryu J et al (2011) CHI3L1 (YKL-40) is expressed in human gliomas and regulates the invasion, growth and survival of glioma cells. Int J Cancer J Int Cancer 128:1316-26. doi:10.1002/ijc.25466
90. Xie D, Yin D, Tong X et al (2004) Cyr61 is overexpressed in gliomas and involved in integrin-linked kinase-mediated Akt and beta-catenin-TCF/Lef signaling pathways. Cancer Res 64:1987-1996 (Pubitemid 38339444)
91. Hau P, Kunz-Schughart LA, Rummele P et al (2006) Tenascin-C protein is induced by transforming growth factor-beta1 but does not correlate with time to tumor progression in high-grade gliomas. J Neurooncol 77:1-7. doi:10.1007/s11060-005-9000-5 (Pubitemid 43870555)
92. Leins A, Riva P, Lindstedt R et al (2003) Expression of tenascin-C in various human brain tumors and its relevance for survival in patients with astrocytoma. Cancer 98:2430-9. doi:10.1002/cncr.11796 (Pubitemid 37466658)
93. Zagzag D, Friedlander DR, Miller DC et al (1995) Tenascin expression in astrocytomas correlates with angiogenesis. Cancer Res 55:907-14
94. Zagzag D, Friedlander DR, Dosik J et al (1996) Tenascin-C expression by angiogenic vessels in human astrocytomas and by human brain endothelial cells in vitro. Cancer Res 56:182-9 (Pubitemid 26010398)
95. HiguchiM, Ohnishi T, AritaN et al (1993) Expression of tenascin in human gliomas: its relation to histological malignancy, tumor dedifferentiation and angiogenesis. Acta Neuropathologica 85:481-7 (Pubitemid 23180409)
96. Mahesparan R, Read T-A, Lund-Johansen M et al (2003) Expression of extracellular matrix components in a highly infiltrative in vivo glioma model. Acta Neuropathologica 105:49-57. doi:10.1007/s00401-002-0610-0 (Pubitemid 36798016)
97. Sarkar S, Nuttall RK, Liu S et al (2006) Tenascin-C stimulates glioma cell invasion through matrix metalloproteinase-12. Cancer Res 66:11771-80. doi:10.1158/0008-5472.CAN-05-0470 (Pubitemid 46094189)
98. Deryugina EI, Bourdon MA (1996) Tenascin mediates human glioma cell migration and modulates cell migration on fibronectin. J Cell Sci 109(Pt 3):643-52 (Pubitemid 26092685)
99. Wenk MB, Midwood KS, Schwarzbauer JE (2000) Tenascin-C suppresses Rho activation. J Cell Biol 150:913-20
100. Jung TY, Jung S, Ryu HH et al (2008) Role of galectin-1 in migration and invasion of human glioblastoma multiforme cell lines. J Neurosurg 109:273-284. doi:10.3171/JNS/2008/109/8/0273
101. Rorive S, Belot N, Decaestecker C et al (2001) Galectin-1 is highly expressed in human gliomas with relevance for modulation of invasion of tumor astrocytes into the brain parenchyma. Glia 33:241-255. doi:10.1002/1098- 1136(200103)33:3 (Pubitemid 32219133)
102. Toussaint LG, Nilson AE, Goble JM et al (2012) Galectin-1, a gene preferentially expressed at the tumormargin, promotes glioblastoma cell invasion. Mol Cancer 11:32. doi:10.1186/1476-4598-11-32
103. Camby I, Belot N, Lefranc F et al (2002) Galectin-1 modulates human glioblastoma cell migration into the brain through modifications to the actin cytoskeleton and levels of expression of small GTPases. J Neuropathol Exp Neurol 61:585-96 (Pubitemid 34721463)
104. Camby I, Belot N, Rorive S et al (2001) Galectins are differentially expressed in supratentorial pilocytic astrocytomas, astrocytomas, anaplastic astrocytomas and glioblastomas, and significantly modulate tumor astrocyte migration. Brain Pathol (Zurich, Switzerland) 11:12-26
105. Le Mercier M, Mathieu V, Haibe-Kains B et al (2008) Knocking down galectin 1 in human hs683 glioblastoma cells impairs both angiogenesis and endoplasmic reticulum stress responses. J Neuropathol Exp Neurol 67:456 - 69. doi:10.1097/NEN.0b013e318170f892
106. Debray C, Vereecken P, Belot N et al (2004) Multifaceted role of galectin-3 on human glioblastoma cell motility. Biochem Biophys Res Commun 325:1393-8. doi:10.1016/j.bbrc.2004.10.181 (Pubitemid 39539230)
107. Neder L, Marie SKN, Carlotti CG et al (2004) Galectin-3 as an immunohistochemical tool to distinguish pilocytic astrocytomas from diffuse astrocytomas, and glioblastomas from anaplastic oligodendrogliomas. Brain Pathol (Zurich, Switzerland) 14:399-405 (Pubitemid 39524969)
108. Strik HM, Deininger MH, Frank B et al (2001) Galectin-3: cellular distribution and correlation with WHO-grade in human gliomas. J Neuro-Oncol 53:13-20 (Pubitemid 32936654)
109. Bresalier RS, Yan PS, Byrd JC et al (1997) Expression of the endogenous galactose-binding protein galectin-3 correlates with the malignant potential of tumors in the central nervous system. Cancer 80:776-87 (Pubitemid 27339834)
110. Gordower L, Decaestecker C, Kacem Yet al (1999) Galectin-3 and galectin-3-binding site expression in human adult astrocytic tumours and related angiogenesis. Neuropathol Appl Neurobiol 25:319-30 (Pubitemid 29392712)
111. Coppola D, Szabo M, Boulware D et al (2004) Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies. Clin Cancer Res Off J Am Assoc Cancer Res 10:184-90 (Pubitemid 38114178)
112. Saitoh Y, Kuratsu J, Takeshima H et al (1995) Expression of osteopontin in human glioma. Its correlation with the malignancy. Laboratory investigation. J Tech Methods Pathol 72:55-63
113. Colin C, Baeza N, Bartoli C et al (2006) Identification of genes differentially expressed in glioblastoma versus pilocytic astrocytoma using suppression subtractive hybridization. Oncogene 25:2818-26. doi:10.1038/sj.onc. 1209305
114. Lu D-Y, Yeh W-L, Huang S-M et al (2012) Osteopontin increases heme oxygenase-1 expression and subsequently induces cell migration and invasion in glioma cells. Neuro-Oncol 14:1367-78. doi:10.1093/neuonc/nos262
115. Jan HJ, Lee CC, Shih YL et al (2010) Osteopontin regulates human glioma cell invasiveness and tumor growth in mice. Neuro Oncol 12:58-70. doi:10.1093/neuonc/nop013
116. Rempel SA, Golembieski WA, Fisher JL et al (2001) SPARC modulates cell growth, attachment and migration of U87 glioma cells on brain extracellular matrix proteins. J Neuro-Oncol 53:149-60 (Pubitemid 33034688)
117. Schultz C, Lemke N, Ge S et al (2002) Secreted protein acidic and rich in cysteine promotes glioma invasion and delays tumor growth in vivo. Cancer Res 62:6270-7 (Pubitemid 35244481)
118. Kunigal S, Gondi CS, Gujrati M et al (2006) SPARC-induced migration of glioblastoma cell lines via uPA-uPAR signaling and activation of small GTPase RhoA. Int J Oncol 29:1349-57
119. Seno T, Harada H, Kohno S et al (2009) Downregulation of SPARC expression inhibits cell migration and invasion in malignant gliomas. Int J Oncol 34:707-15
120. McClung HM, Thomas SL, Osenkowski P et al (2007) SPARC upregulates MT1-MMP expression, MMP-2 activation, and the secretion and cleavage of galectin-3 in U87MG glioma cells. Neurosci Lett 419:172-7. doi:10.1016/j.neulet. 2007.04.037 (Pubitemid 46719671)
121. Rich JN, Hans C, Jones B et al (2005) Gene expression profiling and genetic markers in glioblastoma survival. Cancer Res 65:4051-8. doi:10.1158/0008-5472.CAN-04-3936 (Pubitemid 40775641)
122. Wang H, Wang Y, Jiang C (2013) Stromal protein periostin identified as a progression associated and prognostic biomarker in glioma via inducing an invasive and proliferative phenotype. Int J Oncol 42:1716-1724. doi:10.3892/ijo.2013.1847
123. Bello L, Francolini M, Marthyn P et al (2001) Alpha(v)beta3 and alpha(v)beta5 integrin expression in glioma periphery. Neurosurg 49:380-9, discussion 390
124. Kanamori M, Vanden Berg SR, Bergers G et al (2004) Integrin beta3 overexpression suppresses tumor growth in a humanmodel of gliomagenesis: implications for the role of beta3 overexpression in glioblastoma multiforme. Cancer Res 64:2751-2758 (Pubitemid 38500612)
125. Stupp R, Hegi ME, Neyns B et al (2010) Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. J Clin Oncol Off J Am Soc Clin Oncol 28:2712-8. doi:10.1200/JCO.2009.26.6650
126. Reyes SB, Narayanan AS, Lee HS et al (2013) αvβ8 integrin interacts with RhoGDI1 to regulate Rac1 and Cdc42 activation and drive glioblastoma cell invasion. Mol Biol Cell 24:474-82. doi:10.1091/mbc.E12-07-0521
127. Tchaicha JH, Reyes SB, Shin J et al (2011) Glioblastoma angiogenesis and tumor cell invasiveness are differentially regulated by β8 integrin. Cancer Res 71:6371-81. doi:10.1158/0008-5472.CAN-11-0991
128. Nakada M, Nambu E, Furuyama N et al (2013) Integrin α3 is overexpressed in glioma stem-like cells and promotes invasion. Br J Cancer. doi:10.1038/bjc.2013.218
129. Gunal A, Onguru O, Safali M, Beyzadeoglu M (2008) Fascin expression [corrected] in glial tumors and its prognostic significance in glioblastomas. Neuropathol 28:382-386. doi:10.1111/j.1440-1789.2008.00889 (Pubitemid 351798976)
130. Peraud A, Mondal S, Hawkins C et al (2003) Expression of fascin, an actin-bundling protein, in astrocytomas of varying grades. Brain Tumor Pathol 20:53-8 (Pubitemid 38146271)
131. Roma AA, PraysonRA (2005) Fascin expression in 90 patients with glioblastomamultiforme. Ann Diagn Pathol 9:307-11. doi:10.1016/j.anndiagpath. 2005.07.005
132. Hwang JH, Smith CA, Salhia B, Rutka JT (2008) The role of fascin in the migration and invasiveness of malignant glioma cells. Neoplasia 10:149-159 (Pubitemid 351240881)
133. Geiger KD, Stoldt P, Schlote W, Derouiche A (2000) Ezrin immunoreactivity is associated with increasing malignancy of astrocytic tumors but is absent in oligodendrogliomas.AmJ Pathol 157:1785-1793
134. Wick W, Grimmel C, Wild-Bode C et al (2001) Ezrin-dependent promotion of glioma cell clonogenicity, motility, and invasion mediated by BCL-2 and transforming growth factor-beta2. J Neurosci 21:3360-3368 (Pubitemid 32422801)
135. Tynninen O, Carpen O, Jaaskelainen J et al (2004) Ezrin expression in tissue microarray of primary and recurrent gliomas. Neuropathol Appl Neurobiol 30:472-477. doi:10.1111/j.1365-2990.2004.00562.x (Pubitemid 39423034)
136. Li X, Lee AY (2010) Semaphorin 5A and plexin-B3 inhibit human glioma cell motility through RhoGDIalpha-mediated inactivation of Rac1 GTPase. J Biol Chem 285:32436-32445. doi:10.1074/jbc.M110.120451
137. Li X, Law JW, Lee AY (2011) Semaphorin 5A and plexin-B3 regulate human glioma cell motility and morphology through Rac1 and the actin cytoskeleton. Oncogene 31(5):595-610
138. Zhou X, Ma L, Li J et al (2012) Effects of SEMA3G on migration and invasion of glioma cells. Oncol Rep 28:269-75. doi:10.3892/or.2012.1796
139. Zhang W, Nwagwu C, Le DM et al (2003) Increased invasive capacity of connexin43-overexpressing malignant glioma cells. J Neurosurg 99:1039-1046. doi:10.3171/jns.2003.99.6.1039 (Pubitemid 44717400)
140. Strale PO, Clarhaut J, Lamiche C et al (2012) Down-regulation of connexin43 expression reveals the involvement of caveolin-1 containing lipid rafts in human U251 glioblastoma cell invasion. Mol Carcinog 51:845-860. doi:10.1002/mc.20853
141. Terakawa Y, Agnihotri S, Golbourn B et al (2013) The role of drebrin in glioma migration and invasion. Exp Cell Res 319:517-528. doi:10.1016/j.yexcr. 2012.11.008
142. Hu B, Thirtamara-Rajamani KK, Sim H, Viapiano MS (2009) Fibulin-3 is uniquely upregulated in malignant gliomas and promotes tumor cell motility and invasion. Mol Cancer Res 7:1756-1770. doi:10.1158/1541-7786.MCR-09-0207
143. SperanzaMC, Frattini V, Pisati F et al (2012) NEDD9, a novel target of miR-145, increases the invasiveness of glioblastoma. Oncotarget 3:723-734
144. Shi L, SunX, Zhang J et al (2012) Gab2 expression in glioma and its implications for tumor invasion. Acta Oncol. doi:10.3109/0284186X.2012.750032
145. Cattaneo MG, Cappellini E, Vicentini LM (2012) Silencing of Eps8 blocksmigration and invasion in human glioblastoma cell lines. Exp Cell Res 318:1901-1912. doi:10.1016/j.yexcr.2012.05.010
146. Fukushima T, Tezuka T, Shimomura T et al (2007) Silencing of insulin-like growth factor-binding protein-2 in human glioblastoma cells reduces both invasiveness and expression of progression-associated gene CD24. J Biol Chem 282:18634-18644. doi:10.1074/jbc.M609567200 (Pubitemid 47100243)
147. Wang GK, Hu L, Fuller GN, Zhang W (2006) An interaction between insulin-like growth factor-binding protein 2 (IGFBP2) and integrin alpha5 is essential for IGFBP2-induced cell mobility. J Biol Chem 281:14085-91. doi:10.1074/jbc.M513686200 (Pubitemid 43848335)
148. Sallinen SL, Sallinen PK, Haapasalo HK et al (2000) Identification of differentially expressed genes in human gliomas by DNA microarray and tissue chip techniques. Cancer Res 60:6617-22
149. Lin Y, Jiang T, Zhou K et al (2009) Plasma IGFBP-2 levels predict clinical outcomes of patients with high-grade gliomas. Neuro Oncol 11:468-476. doi:10.1215/15228517-2008-114
150. Scrideli CA, Carlotti CG, Mata JF et al (2007) Prognostic significance of co-overexpression of the EGFR/IGFBP-2/HIF-2A genes in astrocytomas. JNeuro-Oncol 83:233-9. doi:10.1007/s11060-007-9328-0 (Pubitemid 46952233)
151. Freije WA, Castro-Vargas FE, Fang Z et al (2004) Gene expression profiling of gliomas strongly predicts survival. Cancer Res 64:6503-10. doi:10.1158/0008-5472.CAN-04-0452 (Pubitemid 39297907)
152. McDonald KL, O'Sullivan MG, Parkinson JF et al (2007) IQGAP1 and IGFBP2: valuable biomarkers for determining prognosis in glioma patients. J Neuropathol Exp Neurol 66:405-417. doi:10.1097/nen.0b013e31804567d7 00005072-200705000-00010
153. Elmlinger MW, Deininger MH, Schuett BS et al (2001) In vivo expression of insulin-like growth factor-binding protein-2 in human gliomas increases with the tumor grade. Endocrinology 142:1652-8 (Pubitemid 32299696)
154. Song SW, Fuller GN, Khan A et al (2003) IIp45, an insulin-like growth factor binding protein 2 (IGFBP-2) binding protein, antagonizes IGFBP-2 stimulation of glioma cell invasion. Proc Natl Acad Sci U S A 100:13970 -13975. doi:10.1073/pnas.2332186100 2332186100 [pii]
155. Song SW, Fuller GN, Zheng H, ZhangW(2005) Inactivation of the invasion inhibitory gene IIp45 by alternative splicing in gliomas. Cancer Res 65:3562-3567. doi:10.1158/0008-5472.CAN-04-3392 (Pubitemid 40616331)
156. Hu B, Shi B, Jarzynka MJ et al (2009) ADP-ribosylation factor 6 regulates glioma cell invasion through the IQ-domain GTPase-activating protein 1-Rac1-mediated pathway. Cancer Res 69:794-801. doi:10.1158/0008-5472.CAN-08- 2110
157. Suvasini R, Shruti B, Thota B et al (2011) Insulin growth factor-2 binding protein 3 (IGF2BP3) is a glioblastoma-specific marker that activates phosphatidylinositol 3-kinase/mitogen-activated protein kinase (PI3K/MAPK) pathways by modulating IGF-2. J Biol Chem 286:25882-25890. doi:10.1074/jbc.M110. 178012
158. Gopal U, Bohonowych JE, Lema-Tome C et al (2011) A novel extracellular Hsp90 mediated co-receptor function for LRP1 regulates EphA2 dependent glioblastoma cell invasion. PloS One 6:e17649. doi:10.1371/journal.pone.0017649
159. Miekus K, Kijowski J, Sekuła M, Majka M (2012) 17AEP-GA, an HSP90 antagonist, is a potent inhibitor of glioblastoma cell proliferation, survival, migration and invasion. Oncol Rep 28:1903-9. doi:10.3892/or.2012.1996
160. Lo HW, Zhu H, Cao X et al (2009) A novel splice variant of GLI1 that promotes glioblastoma cell migration and invasion. Cancer Res 69:6790-6798. doi:10.1158/0008-5472.CAN-09-0886
161. Guan H, Cai J, Zhang N et al (2012) Sp1 is upregulated in human glioma, promotes MMP-2-mediated cell invasion and predicts poor clinical outcome. Int J Cancer J Int Cancer 130:593-601. doi:10.1002/ijc.26049
162. Cao S, Wang C, Zheng Q et al (2011) STAT5 regulates glioma cell invasion by pathways dependent and independent of STAT5 DNA binding. Neurosci Lett 487:228-33. doi:10.1016/j.neulet.2010.10.028
163. Merk BC, Owens JL, Lopes M-BS et al (2011) STAT6 expression in glioblastoma promotes invasive growth. BMC Cancer 11:184. doi:10.1186/1471-2407- 11-184
164. Selmi T, Martello A, Vignudelli T et al (2012) ZFP36 expression impairs glioblastoma cell lines viability and invasiveness by targeting multiple signal transduction pathways. Cell Cycle 11:1977-87. doi:10.4161/cc.20309
165. Mikheeva SA, Mikheev AM, Petit A et al (2010) TWIST1 promotes invasion through mesenchymal change in human glioblastoma. Mol Cancer 9:194. doi:10.1186/1476-4598-9-194
166. Elias MC, Tozer KR, Silber JR et al (2005) TWIST is expressed in human gliomas and promotes invasion. Neoplasia 7:824-837
167. Jin X, Jeon H-Y, Joo KM et al (2011) Frizzled 4 regulates stemness and invasiveness of migrating glioma cells established by serial intracranial transplantation. Cancer Res 71:3066-75. doi:10.1158/0008-5472.CAN-10-1495
168. Lipinski CA, Tran NL, Menashi E et al (2005) The tyrosine kinase pyk2 promotes migration and invasion of glioma cells. Neoplasia 7:435-445 (Pubitemid 40791863)
169. Gutenberg A, Bruck W, Buchfelder M, Ludwig HC (2004) Expression of tyrosine kinases FAK and Pyk2 in 331 human astrocytomas. Acta Neuropathol 108:224-230. doi:10.1007/s00401-004-0886-3 (Pubitemid 39199514)
170. Lipinski CA, Tran NL, Viso C et al (2008) Extended survival of Pyk2 or FAK deficient orthotopic glioma xenografts. J Neurooncol 90:181-189. doi:10.1007/s11060-008-9656-8
171. Wang J, Wang Q, Cui Y et al (2012) Knockdown of cyclin D1 inhibits proliferation, induces apoptosis, and attenuates the invasive capacity of human glioblastoma cells. J Neurooncol 106:473-484. doi:10.1007/s11060-011-0692-4
172. Yang L, LiuM, Gu Z et al (2012) Overexpression of SASH1 related to the decreased invasion ability of human glioma U251 cells. Tumour Biol 33:2255-2263. doi:10.1007/s13277-012-0487-z
173. Liu B, Wang L, Shen LL et al (2012) RNAi-mediated inhibition of presenilin 2 inhibits glioma cell growth and invasion and is involved in the regulation of Nrg1/ErbB signaling. Neuro Oncol 14:994-1006. doi:10.1093/neuonc/ nos138
174. Qi S, SongY, PengYet al (2012) ZEB2mediatesmultiple pathways regulating cell proliferation, migration, invasion, and apoptosis in glioma. PLoS One 7:e38842. doi:10.1371/journal.pone.0038842
175. Alonso MM, Diez-Valle R, Manterola L et al (2011) Genetic and epigenetic modifications of Sox2 contribute to the invasive phenotype of malignant gliomas. PLoS One 6:e26740. doi:10.1371/journal.pone.0026740
176. Xu L, ZhuY, Xu J et al (2012) Notch1 activation promotes renal cell carcinoma growth via PI3K/Akt signaling. Cancer Sci 103:1253-8. doi:10.1111/j.1349-7006.2012.02291.x
177. Raghu H, Gondi CS, Dinh DH et al (2011) Specific knockdown of uPA/uPAR attenuates invasion in glioblastoma cells and xenografts by inhibition of cleavage and trafficking of Notch-1 receptor. Mol Cancer 10:130. doi:10.1186/1476-4598-10-130
178. Tao T, Cheng C, Ji Y et al (2012) Numbl inhibits glioma cell migration and invasion by suppressing TRAF5-mediated NF-kappaB activation. Mol Biol Cell 23:2635 -2644. doi:10.1091/mbc.E11-09-0805
179. Pan H, Wang H, Zhu L et al (2011) The role of Nrf2 in migration and invasion of human glioma cell U251.World Neurosurg. doi:10.1016/j.wneu.2011.06. 063
180. Bai J, Mei P-J, Liu H et al (2012) BRG1 expression is increased in human glioma and controls glioma cell proliferation, migration and invasion in vitro. J Cancer Res Clin Oncol 138:991-8. doi:10.1007/s00432-012-1172-8
181. Wang Y, Moncayo G, Morin P Jr et al (2013) Mer receptor tyrosine kinase promotes invasion and survival in glioblastoma multiforme. Oncogene 32:872-882. doi:10.1038/onc.2012.104
182. Li H, Chen L, Zhang A et al (2012) Silencing of IKKε using siRNA inhibits proliferation and invasion of glioma cells in vitro and in vivo. Int J Oncol 41:169-78. doi:10.3892/ijo.2012.1452
183. Luk SK, Piekorz RP, Nürnberg B, Tony To S-S (2012) The catalytic phosphoinositol 3-kinase isoform p110δ is required for glioma cell migration and invasion. Eur J Cancer 48:149-57. doi:10.1016/j.ejca.2011.09.006
184. Feng H, Liu KW, Guo P et al (2012) Dynamin 2 mediates PDGFRα-SHP-2-promoted glioblastoma growth and invasion. Oncogene 31:2691-702. doi:10.1038/onc.2011.436
185. Kwiatkowska A, Didier S, Fortin S et al (2012) The small GTPase RhoG mediates glioblastoma cell invasion. Mol Cancer 11:65. doi:10.1186/1476-4598-11- 65
186. Pang B, Fan H, Zhang IYet al (2012)HMGA1 expression in human gliomas and its correlation with tumor proliferation, invasion and angiogenesis. J Neuro-Oncol 106:543-9. doi:10.1007/s11060-011-0710-6
187. Kobayashi K, Takahashi H, Inoue A et al (2012) Oct-3/4 promotes migration and invasion of glioblastoma cells. J Cell Biochem 113:508-17. doi:10.1002/jcb.23374
188. Burgoyne AM, Phillips-Mason PJ, Burden-Gulley SM et al (2009) Proteolytic cleavage of protein tyrosine phosphatase mu regulates glioblastoma cell migration. Cancer Res 69:6960-8. doi:10.1158/0008-5472.CAN-09-0863
189. Burgoyne AM, Palomo JM, Phillips-Mason PJ et al (2009) PTPmu suppresses glioma cell migration and dispersal. Neuro-Oncol 11:767-78. doi:10.1215/ 15228517-2009-019
190. Quintavalle C, Garofalo M, Zanca C et al (2012) miR-221/222 overexpession in human glioblastoma increases invasiveness by targeting the protein phosphate PTPμ. Oncogene 31:858-68. doi:10.1038/onc.2011.280
191. Chahal M, Xu Y, Lesniak D et al (2010) MGMT modulates glioblastoma angiogenesis and response to the tyrosine kinase inhibitor sunitinib. Neuro-Oncol 12:822-33. doi:10.1093/neuonc/noq017
192. Azoitei N, Kleger A, Schoo N et al (2011) Protein kinase D2 is a novel regulator of glioblastoma growth and tumor formation. Neuro-Oncol 13:710-24. doi:10.1093/neuonc/nor084
193. Bernhart E, Damm S, Wintersperger A et al (2013) Protein kinase D2 regulates migration and invasion of U87MG glioblastoma cells in vitro. Exp Cell Res 319(13):2037-2048
194. Zhou X, Zhan W, Bian W et al (2013) GOLPH3 regulates the migration and invasion of glioma cells though RhoA. Biochem Biophys Res Commun 433:338-44. doi:10.1016/j.bbrc.2013.03.003
195. Li X-Y, Liu W, Chen S-F et al (2011) Expression of the Golgi phosphoprotein-3 gene in human gliomas: a pilot study. J Neuro-Oncol 105:159-63. doi:10.1007/s11060-011-0573-x
196. Zhou J, Xu T, Qin R et al (2012) Overexpression of Golgi phosphoprotein-3 (GOLPH3) in glioblastoma multiforme is associated with worse prognosis. J Neuro-Oncol 110:195-203. doi:10.1007/s11060-012-0970-9
197. Tarassishin L, Lee SC (2013) Interferon regulatory factor 3 alters glioma inflammatory and invasive properties. J Neurooncol. doi:10.1007/s11060-013- 1109-3
198. Huber RM, Rajski M, Sivasankaran B et al (2013) Deltex-1 activates mitotic signaling and proliferation and increases the clonogenic and invasive potential of U373 and LN18 glioblastoma cells and correlates with patient survival. PloS One 8:e57793. doi:10.1371/journal.pone.0057793
199. Liang Y, Bollen AW, Aldape KD, Gupta N (2006) Nuclear FABP7 immunoreactivity is preferentially expressed in infiltrative glioma and is associated with poor prognosis in EGFR-overexpressing glioblastoma. BMC Cancer 6:97. doi:10.1186/1471-2407-6-97
200. De Stefano D, Tommonaro G, Malik SA et al (2012) Cacospongionolide and scalaradial, two marine sesterterpenoids as potent apoptosis-inducing factors in human carcinoma cell lines. PloS One 7:e33031. doi:10.1371/journal.pone.0033031
201. Kaloshi G, Mokhtari K, Carpentier C et al (2007) FABP7 expression in glioblastomas: relation to prognosis, invasion and EGFR status. J Neuro-Oncol 84:245-8. doi:10.1007/s11060-007-9377-4 (Pubitemid 47108516)
202. Liang Y, Diehn M, Watson N et al (2005) Gene expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma multiforme. Proc Natl Acad Sci U S A 102:5814-9. doi:10.1073/pnas.0402870102 (Pubitemid 40559642)
203. Nakada M, Drake KL, Nakada S et al (2006) Ephrin-B3 ligand promotes glioma invasion through activation of Rac1. Cancer Res 66:8492-500. doi:10.1158/0008-5472.CAN-05-4211 (Pubitemid 44449162)
204. Nakada M, Niska JA, Miyamori H et al (2004) The phosphorylation of EphB2 receptor regulates migration and invasion of human glioma cells. Cancer Res 64:3179-3185 (Pubitemid 38581420)
205. Wykosky J, Gibo DM, Stanton C, Debinski W (2005) EphA2 as a novel molecular marker and target in glioblastoma multiforme. Mol Cancer Res 3:541-551. doi:10.1158/1541-7786.MCR-05-0056 (Pubitemid 41567273)
206. Nakada M, Niska JA, Tran NL et al (2005) EphB2/R-Ras signaling regulates glioma cell adhesion, growth, and invasion. Am J Pathol 167:565-576. doi:10.1016/S0002-9440(10)62998-7 (Pubitemid 43026110)
207. Shimizu A, Nakayama H, Wang P et al (2013) Netrin-1 promotes glioblastoma cell invasiveness and angiogenesis by multiple pathways including activation of RhoA, cathepsin B, and cAMPresponse element-binding protein. J Biol Chem 288:2210-22. doi:10.1074/jbc.M112.397398
208. Ylivinkka I, Hu Y, Chen P et al (2013) Netrin-1 induced activation of Notch signaling mediates glioblastoma cell invasion. J Cell Sci. doi:10.1242/jcs.120022
209. Zhou X, Xu X, Meng Q et al (2013) Bex2 is critical for migration and invasion inmalignant glioma cells. JMol Neurosci:MN 50:78-87. doi:10.1007/s12031-012-9864-8
210. Senner V, Schmidtpeter S, Braune S et al (2003) AMOG/beta2 and glioma invasion: does loss of AMOG make tumour cells run amok? Neuropathol Appl Neurobiol 29:370-377 (Pubitemid 36960338)
211. Persson O, Krogh M, Saal LH et al (2007) Microarray analysis of gliomas reveals chromosomal position-associated gene expression patterns and identifies potential immunotherapy targets. J Neurooncol 85:11-24. doi:10.1007/s11060-007- 9383-6 (Pubitemid 47422652)
212. Seol HJ, Chang JH, Yamamoto J et al (2012) Overexpression of CD99 increases the migration and invasiveness of humanmalignant glioma cells. Genes Cancer 3:535-549. doi:10.1177/1947601912473603
213. Sameshima T, Nabeshima K, Toole BP et al (2000) Expression of EMMPRIN (CD147), a cell surface inducer of matrix metalloproteinases, in normal human brain and gliomas. Int J Cancer 88:21-27. doi:10.1002/1097-0215(20001001)88
214. Liang Q, Xiong H, Gao G et al (2005) Inhibition of basigin expression in glioblastoma cell line via antisense RNA reduces tumor cell invasion and angiogenesis. Cancer Biol Ther 4:759-762 (Pubitemid 41351176)
215. Gu J, Zhang C, Chen R et al (2009) Clinical implications and prognostic value of EMMPRIN/CD147 and MMP2 expression in pediatric gliomas. Eur J Pediatr 168:705-10. doi:10.1007/s00431-008-0828-5
216. Bredel M, Bredel C, Juric D et al (2005) Functional network analysis reveals extended gliomagenesis pathway maps and three novel MYC-interacting genes in human gliomas. Cancer Res 65:8679-8689. doi:10.1158/0008-5472.CAN-05- 1204 (Pubitemid 41377355)
217. Kohno M, Hasegawa H, Miyake M et al (2002) CD151 enhances cell motility and metastasis of cancer cells in the presence of focal adhesion kinase. Int J Cancer 97:336-343. doi:10.1002/ijc.1605 [pii] (Pubitemid 34049024)
218. Enloe BM, Jay DG (2011) Inhibition of Necl-5 (CD155/PVR) reduces glioblastoma dispersal and decreases MMP-2 expression and activity. J Neurooncol 102:225-235. doi:10.1007/s11060-010-0323-5
219. Sloan KE, Stewart JK, Treloar AF et al (2005) CD155/PVR enhances glioma cell dispersal by regulating adhesion signaling and focal adhesion dynamics. Cancer Res 65:10930-7. doi:10.1158/0008-5472.CAN-05-1890 (Pubitemid 41713361)
220. Maherally Z, Smith JR, An Q, Pilkington GJ (2012) Receptors for hyaluronic acid and poliovirus: a combinatorial role in glioma invasion? PloS One 7:e30691. doi:10.1371/journal.pone.0030691
221. Kijima N, Hosen N, Kagawa N et al (2012) CD166/activated leukocyte cell adhesion molecule is expressed on glioblastoma progenitor cells and involved in the regulation of tumor cell invasion. Neuro Oncol 14:1254-1264. doi:10.1093/neuonc/nor202
222. Tews DS, Nissen A (1998-1999) Expression of adhesion factors and degrading proteins in primary and secondary glioblastomas and their precursor tumors. Invasion Metastasis 18(5-6):271-284 (Pubitemid 30223703)
223. Sasaki H, Yoshida K, Ikeda E et al (1998) Expression of the neural cell adhesion molecule in astrocytic tumors: an inverse correlation with malignancy. Cancer 82:1921-31 (Pubitemid 28208649)
224. Duenisch P, Reichart R, Mueller U et al (2011) Neural cell adhesion molecule isoform 140 declines with rise of WHO grade in human gliomas and serves as indicator for the invasion zone of multiform glioblastomas and brain metastases. J Cancer Res Clin Oncol 137:399-414. doi:10.1007/s00432-010-0888-6
225. Todaro L, Christiansen S, VarelaMet al (2007) Alteration of serum and tumoral neural cell adhesion molecule (NCAM) isoforms in patients with brain tumors. J Neuro-Oncol 83:135-44. doi:10.1007/s11060-006-9312-0 (Pubitemid 46784986)
226. Owens GC, Orr EA, DeMasters BK et al (1998) Overexpression of a transmembrane isoform of neural cell adhesionmolecule alters the invasiveness of rat CNS-1 glioma. Cancer Res 58:2020-8 (Pubitemid 28217482)
227. Edvardsen K, Pedersen PH, Bjerkvig R et al (1994) Transfection of glioma cells with the neural-cell adhesion molecule NCAM: effect on glioma-cell invasion and growth in vivo. Int J Cancer J Int Cancer 58:116-22 (Pubitemid 24213978)
228. Edvardsen K, Brünner N, Spang-Thomsen M et al (1993) Migratory, invasive and metastatic capacity of NCAM transfected rat glioma cells. Int J Dev Neurosci Off J Int Soc Dev Neurosci 11:681-90
229. Suzuki M, Suzuki M, Nakayama J et al (2005) Polysialic acid facilitates tumor invasion by glioma cells. Glycobiology 15:887-94. doi:10.1093/glycob/ cwi071 (Pubitemid 41226404)
230. Amoureux M-C, Coulibaly B, Chinot O et al (2010) Polysialic acid neural cell adhesion molecule (PSA-NCAM) is an adverse prognosis factor in glioblastoma, and regulates olig2 expression in glioma cell lines. BMC Cancer 10:91. doi:10.1186/1471-2407-10-91
231. Strojnik T, Røsland GV, Sakariassen PO et al (2007) Neural stem cell markers, nestin and musashi proteins, in the progression of human glioma: correlation of nestin with prognosis of patient survival. Surg Neurol 68:133-43. doi:10.1016/j.surneu.2006.10.050, discussion 143-4
232. ZhangM, Song T, Yang L et al (2008) Nestin and CD133: valuable stem cell-specific markers for determining clinical outcome of glioma patients. J Exp Clin Cancer Res: CR 27:85. doi:10.1186/1756-9966-27-85
233. Ishiwata T, Teduka K, Yamamoto T et al (2011) Neuroepithelial stemcellmarker nestin regulates themigration, invasion and growth of human gliomas. Oncol Rep 26:91-9. doi:10.3892/or.2011.1267
234. Mishima K, Kato Y, Kaneko MK et al (2006) Increased expression of podoplanin in malignant astrocytic tumors as a novel molecular marker of malignant progression. Acta Neuropathol 111:483-488. doi:10.1007/s00401-006- 0063-y
235. Peterziel H, Müller J, Danner A et al (2012) Expression of podoplanin in human astrocytic brain tumors is controlled by the PI3K-AKT-AP-1 signaling pathway and promoter methylation. Neuro-Oncology 14:426-39. doi:10.1093/neuonc/nos055
236. Cortez MA, Nicoloso MS, Shimizu M et al (2010) miR-29b and miR-125a regulate podoplanin and suppress invasion in glioblastoma. Genes Chromosomes Cancer 49:981-90. doi:10.1002/gcc.20808
237. Van den Boom J, Wolter M, Blaschke B et al (2006) Identification of novel genes associated with astrocytoma progression using suppression subtractive hybridization and real-time reverse transcriptionpolymerase chain reaction. Int J Cancer 119:2330-2338. doi:10.1002/ijc.22108 (Pubitemid 44546952)
238. Ji H, Wang J, Fang B et al (2011) alpha-Catenin inhibits glioma cell migration, invasion, and proliferation by suppression of betacatenin transactivation. J Neurooncol 103:445-451. doi:10.1007/s11060-010-0413-4
239. Wan Z, Shi W, Shao B et al (2011) Peroxisome proliferator-activated receptor gamma agonist pioglitazone inhibits beta-catenin-mediated glioma cell growth and invasion. Mol Cell Biochem 349:1-10. doi:10.1007/s11010-010-0637-9
240. Guo G, Kuai D, Cai S et al (2013) Knockdown of FRAT1 expression by RNA interference inhibits human glioblastoma cell growth, migration and invasion. PloS One 8:e61206. doi:10.1371/journal.pone.0061206
241. Ou Y, Ma L, Dong L et al (2013) Migfilin protein promotes migration and invasion in human glioma through epidermal growth factor receptor-mediated phospholipase C-gamma and STAT3 protein signaling pathways. J Biol Chem 288:10948. doi:10.1074/jbc.A112.393900
242. Eckerich C, Zapf S, Fillbrandt R et al (2007) Hypoxia can induce c-Met expression in glioma cells and enhance SF/HGF-induced cell migration. Int J Cancer J Int Cancer 121:276-83. doi:10.1002/ijc.22679 (Pubitemid 46917695)
243. Li Y, Li A, Glas M et al (2011) c-Met signaling induces a reprogramming network and supports the glioblastoma stem-like phenotype. Proc Natl Acad Sci U S A 108:9951-6. doi:10.1073/pnas.1016912108
244. Martens T, Schmidt N-O, Eckerich C et al (2006) A novel one-armed anti-c-Met antibody inhibits glioblastoma growth in vivo. Clin Cancer Res Off J Am Assoc Cancer Res 12:6144-52. doi:10.1158/1078-0432.CCR-05-1418 (Pubitemid 44703780)
245. Liu D, Martin V, Fueyo J et al (2010) Tie2/TEK modulates the interaction of glioma and brain tumor stem cells with endothelial cells and promotes an invasive phenotype. Oncotarget 1:700-9
246. Lee O-H, Xu J, Fueyo J et al (2006) Expression of the receptor tyrosine kinase Tie2 in neoplastic glial cells is associated with integrin beta1-dependent adhesion to the extracellular matrix. Mol Cancer Res 4:915-26. doi:10.1158/1541-7786.MCR-06-0184 (Pubitemid 46121550)
247. Koga K, Todaka T, Morioka M et al (2001) Expression of angiopoietin-2 in human glioma cells and its role for angiogenesis. Cancer Res 61:6248-54 (Pubitemid 32762564)
248. Hu B, Guo P, Fang Q et al (2003) Angiopoietin-2 induces human glioma invasion through the activation of matrix metalloprotease-2. Proc Natl Acad Sci U S A 100:8904 - 9. doi:10.1073/pnas.1533394100
249. Auf G, Jabouille A, Guérit S et al (2010) Inositol-requiring enzyme 1alpha is a key regulator of angiogenesis and invasion in malignant glioma. Proc Natl Acad Sci U S A 107:15553-8. doi:10.1073/pnas.0914072107
250. Zagzag D, Zhong H, Scalzitti JM et al (2000) Expression of hypoxia-inducible factor 1alpha in brain tumors: association with angiogenesis, invasion, and progression. Cancer 88:2606-18 (Pubitemid 30331970)
251. Méndez O, Zavadil J, EsencayM et al (2010) Knock down of HIF-1alpha in glioma cells reduces migration in vitro and invasion in vivo and impairs their ability to form tumor spheres. Mol Cancer 9:133. doi:10.1186/1476-4598-9-133
252. Fujiwara S, Nakagawa K, Harada H et al (2007) Silencing hypoxia-inducible factor-1alpha inhibits cell migration and invasion under hypoxic environment inmalignant gliomas. Int J Oncol 30:793-802
253. Shen SH, Kwan AL, Chen YY, Wang ZX (2013) Effect of silencing HIF-1α on proliferation, invasion and migration of glioblastoma U87 cells. Neurol Sci Off J Ital Neurol Soc Ital Soc Clin Neurophysiol 34:365-71. doi:10.1007/s10072-012-1010-4
254. Dreyfuss JM, Johnson MD, Park PJ (2009) Meta-analysis of glioblastoma multiforme versus anaplastic astrocytoma identifies robust gene markers. Mol Cancer 8:71. doi:10.1186/1476-4598-8-71
255. Salmaggi A, Eoli M, Frigerio S et al (2003) Intracavitary VEGF, bFGF, IL-8, IL-12 levels in primary and recurrent malignant glioma. J Neuro-Oncol 62:297-303 (Pubitemid 36591966)
256. Zhou X, Liu Z, Shi Q et al (2013) Geranylgeranyltransferase I regulates HIF-1α promoting glioblastoma cell migration and invasion. J Neurooncol 112:365-74. doi:10.1007/s11060-013-1081-y
257. Kolesnikova TV, Kazarov AR, Lemieux ME et al (2009) Glioblastoma inhibition by cell surface immunoglobulin protein EWI-2, in vitro and in vivo. Neoplasia 11:77-86, 4p following 86
258. Tran NL, McDonough WS, Savitch BA et al (2006) Increased fibroblast growth factor-inducible 14 expression levels promote glioma cell invasion via Rac1 and nuclear factor-kappaB and correlate with poor patient outcome. Cancer Res 66:9535-9542. doi:10.1158/0008-5472.CAN-06-0418 (Pubitemid 44623652)
259. Tran NL, McDonough WS, Donohue PJ et al (2003) The human Fn14 receptor gene is up-regulated in migrating glioma cells in vitro and overexpressed in advanced glial tumors. Am J Pathol 162:1313-1321. doi:10.1016/S0002-9440(10) 63927-2 (Pubitemid 36350675)
260. Paulino VM, Yang Z, Kloss J et al (2010) TROY (TNFRSF19) is overexpressed in advanced glial tumors and promotes glioblastoma cell invasion via Pyk2-Rac1 signaling. Mol Cancer Res 8:1558-1567. doi:10.1158/1541-7786.MCR-10-0334
261. Fortin SP, Ennis MJ, Schumacher CA et al (2012) Cdc42 and the guanine nucleotide exchange factors Ect2 and trio mediate Fn14-induced migration and invasion of glioblastoma cells. Mol Cancer Res 10:958-968. doi:10.1158/1541- 7786.MCR-11-0616
262. Peng Z, Shuangzhu Y, Yongjie J et al (2013) TNF receptor-associated factor 6 regulates proliferation, apoptosis, and invasion of glioma cells. Mol Cell Biochem 377:87-96. doi:10.1007/s11010-013-1573-2
263. Goplen D, Wang J, Enger PO et al (2006) Protein disulfide isomerase expression is related to the invasive properties of malignant glioma. Cancer Res 66:9895-9902. doi:10.1158/0008-5472.CAN-05-4589 (Pubitemid 44672041)
264. Rutkowski MJ, Sughrue ME, Kane AJ et al (2011) Epidermal growth factor module-containing mucin-like receptor 2 is a newly identified adhesion G protein-coupled receptor associated with poor overall survival and an invasive phenotype in glioblastoma. J Neurooncol. doi:10.1007/s11060-011-0576-7
265. Kane AJ, Sughrue ME, Rutkowski MJ et al (2010) EMR-3: a potential mediator of invasive phenotypic variation in glioblastoma and novel therapeutic target. Neurorep 21:1018-22. doi:10.1097/WNR.0b013e32833f19f2
266. Chidambaram A, Fillmore HL, Van Meter TE et al (2012) Novel report of expression and function of CD97 in malignant gliomas: correlation withWilms tumor 1 expression and glioma cell invasiveness. J Neurosurg 116:843-853. doi:10.3171/2011.11.JNS111455
267. Safaee M, Clark AJ, Oh MC et al (2013) Overexpression of CD97 confers an invasive phenotype in glioblastoma cells and is associated with decreased survival of glioblastoma patients. PLoS One 8:e62765. doi:10.1371/journal.pone. 0062765
268. Huang J, Chen K, Gong W et al (2008) Receptor "hijacking" by malignant glioma cells: a tactic for tumor progression. Cancer Lett 267:254-261. doi:10.1016/j.canlet.2008.03.014
269. Zhou Y, Bian X, Le Yet al (2005) Formylpeptide receptor FPR and the rapid growth of malignant human gliomas. JNatl Cancer Inst 97:823-835. doi:10.1093/jnci/dji142 (Pubitemid 40909125)
270. Yao XH, Ping YF, Chen JH et al (2008) Production of angiogenic factors by human glioblastoma cells following activation of the Gprotein coupled formylpeptide receptor FPR. J Neurooncol 86:47-53. doi:10.1007/s11060-007-9443-y
271. Huang J, Chen K, Chen J et al (2010) The G-protein-coupled formylpeptide receptor FPR confers a more invasive phenotype on human glioblastoma cells. Br J Cancer 102:1052-1060. doi:10.1038/sj.bjc.6605591
272. Kishi Y, Okudaira S, Tanaka M et al (2006) Autotaxin is overexpressed in glioblastoma multiforme and contributes to cell motility of glioblastoma by converting lysophosphatidylcholine to lysophosphatidic acid. J Biol Chem 281:17492-17500. doi:10.1074/jbc.M601803200
273. Hoelzinger DB, Nakada M, Demuth T et al (2008) Autotaxin: a secreted autocrine/paracrine factor that promotes glioma invasion. J Neurooncol 86:297-309. doi:10.1007/s11060-007-9480-6
274. Yu F, Ng SS, Chow BK et al (2011) Knockdown of interferon-induced transmembrane protein 1 (IFITM1) inhibits proliferation, migration, and invasion of glioma cells. J Neurooncol 103:187-195. doi:10.1007/s11060-010-0377-4
275. Ma Y, Wang B, Li W et al (2011) Intersectin1-s is involved in migration and invasion of human glioma cells. J Neurosci Res 89:1079-1090. doi:10.1002/jnr.22616
276. Soroceanu L, Matlaf L, Bezrookove V et al (2011) Human cytomegalovirus US28 found in glioblastoma promotes an invasive and angiogenic phenotype. Cancer Res 71:6643-6653. doi:10.1158/0008-5472.CAN-11-0744
277. Lemke D, Pfenning PN, Sahm F et al (2012) Costimulatory protein 4IgB7H3 drives the malignant phenotype of glioblastoma by mediating immune escape and invasiveness. Clin Cancer Res 18:105-117. doi:10.1158/1078-0432.CCR-11-0880
278. Zhang J, Sarkar S, Cua R et al (2012) A dialog between glioma and microglia that promotes tumor invasiveness through the CCL2/CCR2/interleukin-6 axis. Carcinogenesis 33:312-319. doi:10.1093/carcin/bgr289
279. Galavotti S, Bartesaghi S, Faccenda D et al (2013) The autophagy-associated factors DRAM1 and p62 regulate cell migration and invasion in glioblastoma stem cells. Oncogene 32:699-712. doi:10.1038/onc.2012.111
280. Lu S, Niu N, Guo H et al (2013) ARK5 promotes glioma cell invasion, and its elevated expression is correlated with poor clinical outcome. Eur J Cancer 49:752-763. doi:10.1016/j.ejca.2012.09.018
281. Van Horssen R, Willemse M, Haeger A et al (2013) Intracellular NAD(H) levels control motility and invasion of glioma cells. Cell Mol Life Sci. doi:10.1007/s00018-012-1249-1
282. Ding T, Gu F, Fu L, Ma YJ (2010) Aquaporin-4 in glioma invasion and an analysis ofmolecularmechanisms. J Clin Neurosci 17:1359-1361. doi:10.1016/j.jocn.2010.02.014
283. Lui VC, Lung SS, Pu JK et al (2010) Invasion of human glioma cells is regulated by multiple chloride channels including ClC-3. Anticancer Res 30:4515-4524
284. Garzon-Muvdi T, Schiapparelli P, Aprhys C et al (2012) Regulation of brain tumor dispersal by NKCC1 through a novel role in focal adhesion regulation. PLoS Biol 10:e1001320. doi:10.1371/journal.pbio.1001320
285. Haas BR, Cuddapah VA, Watkins S et al (2011) With-No-Lysine Kinase 3 (WNK3) stimulates glioma invasion by regulating cell volume. Am J Physiol Cell Physiol 301:C1150-60. doi:10.1152/ajpcell.00203.2011
286. Motiani RK, Hyzinski-Garcia MC, Zhang X et al (2013) STIM1 and Orai1 mediate CRAC channel activity and are essential for human glioblastoma invasion. Pflugers Arch. doi:10.1007/s00424-013-1254-8
287. Wang Q, Qian J, Wang J et al (2013) Knockdown of RLIP76 expression byRNAinterference inhibits invasion, induces cell cycle arrest, and increases chemosensitivity to the anticancer drug temozolomide in glioma cells. J Neurooncol 112:73-82. doi:10.1007/s11060-013-1045-2
288. Brat DJ, Bellail AC, Van Meir EG (2005) The role of interleukin-8 and its receptors in gliomagenesis and tumoral angiogenesis.Neuro- Oncol 7:122-33. doi:10.1215/S1152851704001061 (Pubitemid 40590513)
289. Reynés G, Vila V, Martín M et al (2011) Circulating markers of angiogenesis, inflammation, and coagulation in patients with glioblastoma. J Neuro-Oncol 102:35-41. doi:10.1007/s11060-010-0290-x
290. Sun S, Wang Q, Giang A et al (2011) Knockdown of CypA inhibits interleukin-8 (IL-8) and IL-8-mediated proliferation and tumor growth of glioblastoma cells through down-regulated NF-κB. J Neuro-Oncol 101:1-14. doi:10.1007/s11060-010-0220-y
291. Rolhion C, Penault-Llorca F, Kémény JL et al (2001) Interleukin-6 overexpression as a marker of malignancy in human gliomas. J Neurosurg 94:97-101. doi:10.3171/jns.2001.94.1.0097 (Pubitemid 32799478)
292. Li R, Li G, Deng L et al (2010) IL-6 augments the invasiveness of U87MG human glioblastoma multiforme cells via up-regulation of MMP-2 and fascin-1. Oncol Rep 23:1553-9
293. Liu Q, Li G, Li R et al (2010) IL-6 promotion of glioblastoma cell invasion and angiogenesis in U251 and T98G cell lines. J Neuro-Oncol 100:165-76. doi:10.1007/s11060-010-0158-0
294. Wang H, Lathia JD, Wu Q et al (2009) Targeting interleukin 6 signaling suppresses glioma stem cell survival and tumor growth. Stem Cells 27:2393-404. doi:10.1002/stem.188
295. Tchirkov A, Khalil T, Chautard E et al (2007) Interleukin-6 gene amplification and shortened survival in glioblastoma patients. Br J Cancer 96:474-6. doi:10.1038/sj.bjc.6603586 (Pubitemid 46215219)
296. Chang C-Y, Li M-C, Liao S-L et al (2005) Prognostic and clinical implication of IL-6 expression in glioblastoma multiforme. J Clin Neurosci Off J Neurosurg Soc Australas 12:930-3. doi:10.1016/j.jocn.2004.11.017
297. Sciaccaluga M, Fioretti B, Catacuzzeno L et al (2010) CXCL12-induced
298. ZagzagD, Lukyanov Y, Lan L et al (2006) Hypoxia-inducible factor 1 and VEGF upregulate CXCR4 in glioblastoma: implications for angiogenesis and glioma cell invasion. Laboratory investigation. J Tech Methods Pathol 86:1221-32. doi:10.1038/labinvest.3700482 (Pubitemid 44789912)
299. Ehtesham M, Winston JA, Kabos P, Thompson RC (2006) CXCR4 expression mediates glioma cell invasiveness. Oncogene 25:2801-6. doi:10.1038/sj.onc. 1209302
300. Zagzag D, Esencay M, Mendez O et al (2008) Hypoxia- and vascular endothelial growth factor-induced stromal cell-derived factor-1alpha/CXCR4 expression in glioblastomas: one plausible explanation of Scherer's structures. Am J Pathol 173:545-60. doi:10.2353/ajpath.2008.071197
301. Ehtesham M, Mapara KY, Stevenson CB, Thompson RC (2009) CXCR4 mediates the proliferation of glioblastoma progenitor cells. Cancer Lett 274:305-12. doi:10.1016/j.canlet.2008.09.034
302. Maderna E, Salmaggi A, Calatozzolo C et al (2007) Nestin, PDGFRbeta, CXCL12 and VEGF in glioma patients: different profiles of (pro-angiogenic) molecule expression are related with tumor grade and may provide prognostic information. Cancer Biol Ther 6:1018-1024 (Pubitemid 351574951)
303. Bian XW, Yang SX, Chen JH et al (2007) Preferential expression of chemokine receptor CXCR4 by highly malignant human gliomas and its association with poor patient survival. Neurosurg 61:570-579. doi:10.1227/01.NEU.0000290905. 53685.A2
304. Giese A, Bjerkvig R, Berens ME, Westphal M (2003) Cost of migration: invasion of malignant gliomas and implications for treatment. J Clin Oncol Off J Am Soc Clin Oncol 21:1624-36. doi:10.1200/JCO.2003.05.063 (Pubitemid 46594118)
305. Giese A, Westphal M (1996) Glioma invasion in the central nervous system. Neurosurg 39:235-50, discussion 250-2
306. Holland EC (2000) Glioblastoma multiforme: the terminator. Proc Natl Acad Sci U S A 97:6242-4
307. Sciumè G, Santoni A, Bernardini G (2010) Chemokines and glioma: invasion and more. J Neuroimmunol 224:8-12. doi:10.1016/j.jneuroim.2010.05.019
308. Teodorczyk M, Martin-Villalba A (2010) Sensing invasion: cell surface receptors driving spreading of glioblastoma. J Cell Physiol 222:1-10. doi:10.1002/jcp.21901
309. Nakada M, Nakada S, Demuth T et al (2007) Molecular targets of glioma invasion. CellMol Life Sci:CMLS 64:458-78. doi:10.1007/s00018-007-6342-5
310. Chicoine MR, Silbergeld DL (1995) The in vitro motility of human gliomas increases with increasing grade of malignancy. Cancer 75:2904-9
311. Janiak M, Hashmi HR, Janowska-Wieczorek A (1994) Use of the Matrigel-based assay to measure the invasiveness of leukemic cells. Exp Hematol 22:559-65 (Pubitemid 24300489)
312. Jung S, Ackerley C, Ivanchuk S et al (2001) Tracking the invasiveness of human astrocytoma cells by using green fluorescent protein in an organotypical brain slice model. J Neurosurg 94:80-9. doi:10.3171/jns.2001.94.1.0080 (Pubitemid 32799476)
313. TateMC, AghiMK (2009) Biology of angiogenesis and invasion in glioma. Neurotherapeutics J Am Soc Exp NeuroTherapeutics 6:447-57. doi:10.1016/j.nurt. 2009.04.001
314. Lucio-Eterovic AK, Piao Y, De Groot JF (2009) Mediators of glioblastoma resistance and invasion during antivascular endothelial growth factor therapy. Clin Cancer Res Off J Am Assoc Cancer Res 15:4589-99. doi:10.1158/1078-0432.CCR- 09-0575
315. Wang H, Wang H, Shen Wet al (2003) Insulin-like growth factor binding protein 2 enhances glioblastoma invasion by activating invasion-enhancing genes. Cancer Res 63:4315-21 (Pubitemid 36950996)
316. Mehrian-Shai R, Chen CD, Shi T et al (2007) Insulin growth factor-binding protein 2 is a candidate biomarker for PTEN status and PI3K/Akt pathway activation in glioblastoma and prostate cancer. Proc Natl Acad Sci U S A 104:5563 - 8. doi:10.1073/pnas. 0609139104
317. Fan H, Guo H, Zhang IY et al (2011) The different HMGA1 expression of total population of glioblastoma cell line U251 and glioma stemcells isolated fromU251. Brain Res 1384:9-14. doi:10.1016/j.brainres.2011.01.105
318. LiM, Mukasa A, IndaMMet al (2011) Guanylate binding protein 1 is a novel effector of EGFR-driven invasion in glioblastoma. J Exp Med 208:2657-2673. doi:10.1084/jem.20111102
319. Demuth T, Berens ME(2004) Molecularmechanisms of glioma cell migration and invasion. J Neurooncol 70:217-228. doi:10.1007/s11060-004-2751-6 (Pubitemid 39545733)
320. Peruzzi P, Chiocca EA (2011) Understanding glioma invasion: a necessity for effective therapy. World Neurosurgery. doi:10.1016/j.wneu.2011.10.003